You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《藍籌業績》石藥集團(01093.HK)去年純利升8.6%至56億人民幣 末期息10港仙
阿思達克 03-22 12:07
石藥集團(01093.HK)公佈截至去年12月底止全年業績,營業額278.67億元人民幣(下同),按年升11.7%。純利56.05億元,按年升8.6%;每股盈利46.89分。派末期息10港仙,上年同期派9港仙。全年股息爲每股18港仙。 期內,毛利率略爲上升0.9個百分點,主要因爲成藥業務的產品結構變化及原料產品的銷售價格上漲所致。 去年,集團研發費用34.33億元人民幣,按年增18.8%。目前在研項目約300項,主要聚焦在腫瘤、免疫和呼吸、精神神經、代謝、心腦血管系統及抗感染治療領域。逾50個重點候選藥物已進入臨牀或申報階段,其中2個已遞交NDA。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account